The South American Glabellar Experience Study (SAGE)

Banegas, Raul A.; Farache, Fernando; Rancati, Alberto; Chain, Myriam; Gallagher, Conor J.; Chapman, Mary Ann; Caulkins, Carrie

doi:10.1177/1090820x13503475

Cited by 14 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Na medicina estética, a injeção de BoNT/A na região glabelar é uma intervenção comumente usada (Banegas et al, 2013). Além de seus benefícios cosméticos, o tratamento com a aplicação da BoNT/A, parece melhorar o bem-estar emocional, melhorar o comportamento social e psicológico e reduzir a irritabilidade, bem como humores deprimidos e ansiosos (Sommer et al, 2003;Lewis et al, 2009;Sukiankis et al, 2022;Davis et al, 2010).…”

Section: Visão Geral Das Neurotoxinas Botulínicasunclassified

A toxina botulínica na estética facial e o processamento das emoções

Vieira,

Sousa

2024

RSD

View full text Add to dashboard Cite

A ação das toxinas botulínicas é resultado de sua potente capacidade de inibir a liberação de neurotransmissores. Nesse sentido, as toxinas botulínicas apresentam um amplo espectro de indicações, tanto cosméticas, quanto terapêuticas. Dessa forma, este estudo teve como objetivo realizar uma pesquisa bibliográfica sobre a utilização da toxina botulínica Tipo A (BoNT/A) na estética facial e no processamento das emoções. Para isso, foram avaliados ensaios clínicos randomizados (ECRs) que analisassem os efeitos da BoNT/A em pacientes com transtornos de humor, com ênfase na depressão. A pesquisa foi realizada nos bancos de dados PubMed, SCIELO, Web of Science e LILACS, utilizando descritores DeCS/MeSH, tendo sido incluídos os artigos publicados em português e inglês entre os anos de 2003 a 2023. Após aplicação dos critérios, 13 artigos foram selecionados para análise. No geral, a BoNT/A mostrou-se como sendo uma alternativa para melhorar significativamente os sinais faciais de depressão quando comparado ao placebo nos estudos realizados. Na maioria dos ECRs a BoNT/A foi aplicada nos músculos mímicos do terço superior do rosto, na área glabelar, a qual esteve relacionada com a melhora dos transtornos de humor com alvo no feedback facial. Assim, evidências clínicas apontam para que o manejo dos distúrbios emocionais abranja a utilização da terapia com uso da toxina botulínica.

show abstract

Section: Visão Geral Das Neurotoxinas Botulínicasunclassified

A toxina botulínica na estética facial e o processamento das emoções

Vieira,

Sousa

2024

RSD

View full text Add to dashboard Cite

show abstract

“…Although pharmacological and psychological treatment for depression are available, a considerable proportion of depressed patients are resistant to current standard treatment (38,39). In esthetic medicine, the injection of BoNT/A in the glabellar region is a commonly used intervention (40). The contraction of the corrugator muscles is able to produce glabellar frown lines, which is also required for the facial expression of negative emotion, such as anger, fear, and/or sadness (41).…”

Section: Bont/a Therapy For Depression: Clinical Evidencementioning

confidence: 99%

Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective

Liu

Luo

2021

Front. Psychiatry

View full text Add to dashboard Cite

Depression is one of the most common mental disorders, which causes global burden. Antidepressants and psychotherapies are the mainstay of treatment for depression, which have limited efficacy. Thus, alternative approaches for preventing and treating depression are urgently required. Recent clinical trials and preclinical researches have clarified that peripheral facial injection of botulinum neurotoxin type A (BoNT/A) is a rapid, effective and relative safe therapy for improving some symptoms of depression. Despite its safety and efficacy, the underlying therapeutic mechanisms of BoNT/A for depression remains largely unclear. In the present review, we updated and summarized the clinical and preclinical evidence supporting BoNT/A therapy for the treatment of depression. We further discussed the potential mechanisms underlying therapeutic effects of BoNT/A on depression. Notably, we recently identified that the anti-depressant effects of BoNT/A associated with up-regulation of 5-HT levels and brain-derived neurotrophic factor (BDNF) expression in the hippocampus in a preclinical mouse model. In summary, these studies suggest that BoNT/A therapy is a potential effective and safe intervention for the management of depression. However, fundamental questions remain regarding the future prospects of BoNT/A therapy, including safety, efficacy, dose-response relationships, identification of potential predictors of response, and the precise mechanisms underlying BoNT/A therapy.

show abstract

“…Several studies indicate that duration covaries with patient satisfaction. 77 , 78 In a meta-analysis of 621 subjects treated with 20 units of onabotulinumtoxinA for glabellar lines, 84% were responders; among responders, the median duration of effect was 120 days at maximum contraction and 131 days at repose, and satisfaction increased with duration of effect. 77 Additionally, a real-world clinical study in Argentina found that 92 of 110 women treated for glabellar lines switched back to onabotulinumtoxinA from incobotulinumtoxinA, most commonly due to insufficient duration with incobotulinumtoxinA (61 of 92), although the products were used at comparable doses.…”

Section: Preclinical and Clinical Comparison Of Bonta Productsmentioning

confidence: 99%

“… 77 Additionally, a real-world clinical study in Argentina found that 92 of 110 women treated for glabellar lines switched back to onabotulinumtoxinA from incobotulinumtoxinA, most commonly due to insufficient duration with incobotulinumtoxinA (61 of 92), although the products were used at comparable doses. 78 A retrospective study of 50 patients treated with onabotulinumtoxinA for blepharospasm and then switched to incobotulinumtoxinA found that comparable numbers of patients preferred each product (24 versus 26 of 50), with those preferring incobotulinumtoxinA believing it to be more effective and those preferring onabotulinumtoxinA believing it to have a longer duration (significant difference in treatment intervals of 13 weeks versus 10.2 weeks; P =0.017). 79 …”

Section: Preclinical and Clinical Comparison Of Bonta Productsmentioning

confidence: 99%

Botulinum toxin type A products are not interchangeable: a review of the evidence

Brin¹,

James²,

Maltman³

2014

BTT

116

View full text Add to dashboard Cite

Botulinum toxin type A (BoNTA) products are injectable biologic medications derived from Clostridium botulinum bacteria. Several different BoNTA products are marketed in various countries, and they are not interchangeable. Differences between products include manufacturing processes, formulations, and the assay methods used to determine units of biological activity. These differences result in a specific set of interactions between each BoNTA product and the tissue injected. Consequently, the products show differences in their in vivo profiles, including preclinical dose response curves and clinical dosing, efficacy, duration, and safety/adverse events. Most, but not all, published studies document these differences, suggesting that individual BoNTA products act differently depending on experimental and clinical conditions, and these differences may not always be predictable. Differentiation through regulatory approvals provides a measure of confidence in safety and efficacy at the specified doses for each approved indication. Moreover, the products differ in the amount of study to which they have been subjected, as evidenced by the number of publications in the peer-reviewed literature and the quantity and quality of clinical studies. Given that BoNTAs are potent biological products that meet important clinical needs, it is critical to recognize that their dosing and product performance are not interchangeable and each product should be used according to manufacturer guidelines.

show abstract

The South American Glabellar Experience Study (SAGE)

Abstract: In this real-world setting, subjects did not appear to perceive the same facial aesthetic benefits from incobotulinumtoxinA as onabotulinumtoxinA when the products were administered at comparable doses.

Cited by 14 publications

References 9 publications

A toxina botulínica na estética facial e o processamento das emoções

A toxina botulínica na estética facial e o processamento das emoções

Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective

Botulinum toxin type A products are not interchangeable: a review of the evidence

Contact Info

Product

Resources

About